If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 16

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Ma

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Protocol No
ADP-0000-001-SCR
Categories
Cancer, Gynecologic Cancers, Prostate and Urologic Cancers, Other Respiratory, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Ovary, Thoracic Cancers, Sarcoma, Skin Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus, Colorectal

High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)

A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Categories
Cancer, Colorectal, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers, Breast Cancers, Brain and Spine Cancers, Other Respiratory, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Ovary, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus

A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors

A Phase 1 Study of Spyk04 as Monotherapy in Patients with Solid Tumors
Protocol No
CHUGAI-SPK101JG
Categories
Cancer, Ovary, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Breast Cancers, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus, Colorectal, Gynecologic Cancers

An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses

IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer, Colorectal, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Breast Cancers, Lung, Esophagus, Melanoma, Skin, Other Urologic, Bladder, Lip, Oral Cavity and Pharynx, Larynx, Ovary, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
Categories
Cancer, Gynecologic Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Prostate and Urologic Cancers, Gastrointestinal Cancers, Esophagus, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Uterine, Ovary, Cervix, Stomach, Pancreas/Liver, Esophagus, Head and Neck Cancers

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRAS G12C Mutant Advanced Solid Tumors

This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Categories
Cancer, Colorectal, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers, Breast Cancers, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Ovary, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
Protocol No
NRG-BN012
Categories
Cancer, Colorectal, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers, Breast Cancers, Lung, Esophagus, Melanoma, Skin, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Uterine, Ovary, Cervix, Stomach, Pancreas/Liver, Esophagus

Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity >/= 4 Brain Metastases/Year

Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Protocol No
NRG-BN009
Categories
Cancer, Colorectal, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers, Breast Cancers, Lung, Esophagus, Melanoma, Skin, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Uterine, Ovary, Cervix, Stomach, Pancreas/Liver, Esophagus

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer, Colorectal, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Breast Cancers, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Ovary, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus

A Phase 1, Open Label First in Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK 1 Inhibitor GRC 54276 Alone and in Combination with Anti-Pd-1 Monoclonal Antibody Pembrolizumab or Anti-Pd-

A Phase 1 Study of Hpk1 GRC54276 in Combination with Anti-Pd-1 in Patients with Advanced Solid Tumors
Protocol No
GLENMARK-GRC-54276-101
Categories
Cancer, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Ovary, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus, Colorectal, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers, Breast Cancers